GE's $8 billion Abbott deal falls over
Monday, 16 July, 2007
GE Healthcare and Abbott Laboratories have terminated their US$8.13 billion (A$9.5 billion) contract for the sale of Abbott's laboratory and point-of-care diagnostics businesses to GE.
In separate statements, the two companies said they were unable to agree on final terms and conditions of the proposed sale.
The agreement was announced in January this year and was aimed at broadening GE Healthcare's diagnostics business. It did not include Abbott's molecular diagnostics or diabetes units.
At the time, GE said Abbott's in vitro diagnostic technology would complement GE's in vivo diagnostic imaging systems business, as well as its molecular imaging, information technology and patient monitoring units.
Abbott's in vitro diagnostics and point-of-care business generated net sales of approximately $2.7 billion (A$3 billion) last year.
Local newspaper The Chicago Tribune quoted several analysts as saying the price was extravagant and "too good to be true" for Abbott.
AI-designed DNA switches flip genes on and off
The work creates the opportunity to turn the expression of a gene up or down in just one tissue...
Drug delays tumour growth in models of children's liver cancer
A new drug has been shown to delay the growth of tumours and improve survival in hepatoblastoma,...
Ancient DNA rewrites the stories of those preserved at Pompeii
Researchers have used ancient DNA to challenge long-held assumptions about the inhabitants of...
